These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11890872)

  • 21. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.
    Mahipal A; Terai M; Berd D; Chervoneva I; Patel K; Mastrangelo MJ; Sato T
    Cancer Immunol Immunother; 2011 Jul; 60(7):1039-45. PubMed ID: 21519827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
    Lotem M; Merims S; Frank S; Hamburger T; Nissan A; Kadouri L; Cohen J; Straussman R; Eisenberg G; Frankenburg S; Carmon E; Alaiyan B; Shneibaum S; Ozge Ayyildiz Z; Isbilen M; Mert Senses K; Ron I; Steinberg H; Smith Y; Shiloni E; Gure AO; Peretz T
    J Immunol Res; 2016; 2016():8121985. PubMed ID: 27294163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
    Morton DL
    Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine.
    Manne J; Mastrangelo MJ; Sato T; Berd D
    J Immunol; 2002 Sep; 169(6):3407-12. PubMed ID: 12218163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.
    Hsueh EC; Gupta RK; Qi K; Morton DL
    J Clin Oncol; 1998 Sep; 16(9):2913-20. PubMed ID: 9738558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous cancer vaccine: a novel formulation.
    Ohno T
    Microbiol Immunol; 2003; 47(4):255-63. PubMed ID: 12801062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.
    Schreiber S; Kämpgen E; Wagner E; Pirkhammer D; Trcka J; Korschan H; Lindemann A; Dorffner R; Kittler H; Kasteliz F; Küpcü Z; Sinski A; Zatloukal K; Buschle M; Schmidt W; Birnstiel M; Kempe RE; Voigt T; Weber HA; Pehamberger H; Mertelsmann R; Bröcker EB; Wolff K; Stingl G
    Hum Gene Ther; 1999 Apr; 10(6):983-93. PubMed ID: 10223732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.
    Sensi M; Farina C; Maccalli C; Lupetti R; Nicolini G; Anichini A; Parmiani G; Berd D
    J Clin Invest; 1997 Feb; 99(4):710-7. PubMed ID: 9045874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine.
    Berd D; Maguire HC; Mastrangelo MJ; Murphy G
    Cancer Immunol Immunother; 1994 Sep; 39(3):141-7. PubMed ID: 7923243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
    DiFronzo LA; Gupta RK; Essner R; Foshag LJ; O'Day SJ; Wanek LA; Stern SL; Morton DL
    J Clin Oncol; 2002 Aug; 20(15):3242-8. PubMed ID: 12149297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy.
    Murphy GF; Radu A; Kaminer M; Berd D
    J Invest Dermatol; 1993 Mar; 100(3):335S-341S. PubMed ID: 8440919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer.
    Habal N; Gupta RK; Bilchik AJ; Yee R; Leopoldo Z; Ye W; Elashoff RM; Morton DL
    Ann Surg Oncol; 2001 Jun; 8(5):389-401. PubMed ID: 11407512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
    Faries MB; Mozzillo N; Kashani-Sabet M; Thompson JF; Kelley MC; DeConti RC; Lee JE; Huth JF; Wagner J; Dalgleish A; Pertschuk D; Nardo C; Stern S; Elashoff R; Gammon G; Morton DL;
    Ann Surg Oncol; 2017 Dec; 24(13):3991-4000. PubMed ID: 29019177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
    Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
    BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
    Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
    J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma.
    Hsueh EC; Essner R; Foshag LJ; Ye W; Morton DL
    Ann Surg Oncol; 2002 Jun; 9(5):486-92. PubMed ID: 12052761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
    Dillman RO; Beutel LD; Barth NM; de Leon C; O'Connor AA; DePriest C; Nayak SK
    Cancer Biother Radiopharm; 2002 Feb; 17(1):51-66. PubMed ID: 11915174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
    Tan JK; Ho VC
    J Dermatol Surg Oncol; 1993 Nov; 19(11):985-90. PubMed ID: 8245304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.